부산대학교 도서관

Simple Summary: Colonoscopies are effective in the prevention of colorectal cancer (CRC) but considered burdensome. An alternative for or addition to this procedure might be found in circulating tumor DNA (ctDNA) analysis. However, to date, it is not clear which analysis is most suitable for such a ctDNA-based blood test for CRC. Therefore, we assessed this in ten patients with colonoscopies for Lynch syndrome or in the context of the Dutch national screening program who were diagnosed with CRC or its precursor lesion (advanced adenoma). The results of this proof-of-principle study could form the foundation for subsequent studies on ctDNA-based blood test development for CRC screening and management, specifically in carriers of Lynch syndrome. Colorectal cancer (CRC) colonoscopic surveillance is effective but burdensome. Circulating tumor DNA (ctDNA) analysis has emerged as a promising, minimally invasive tool for disease detection and management. Here, we assessed which ctDNA assay might be most suitable for a ctDNA-based CRC screening/surveillance blood test. In this prospective, proof-of-concept study, patients with colonoscopies for Lynch surveillance or the National Colorectal Cancer screening program were included between 7 July 2019 and 3 June 2022. Blood was drawn, and if advanced neoplasia (adenoma with villous component, high-grade dysplasia, ≥10 mm, or CRC) was detected, it was analyzed for chromosomal copy number variations, single nucleotide variants, and genome-wide methylation (MeD-seq). Outcomes were compared with corresponding patients' tissues and the MeD-seq results of healthy blood donors. Two Lynch carriers and eight screening program patients were included: five with CRC and five with advanced adenomas. cfDNA showed copy number variations and single nucleotide variants in one patient with CRC and liver metastases. Eight patients analyzed with MeD-seq showed clustering of Lynch-associated and sporadic microsatellite instable lesions separate from microsatellite stable lesions, as did healthy blood donors. In conclusion, whereas copy number changes and single nucleotide variants were only detected in one patient, cfDNA methylation profiles could discriminate all microsatellite instable advanced neoplasia, rendering this tool particularly promising for LS surveillance. Larger studies are warranted to validate these findings. [ABSTRACT FROM AUTHOR]